

L Number	Hits	Search Text	DB	Time stamp
4	12	Ruvkun NEAR Gary	USPAT; US-PGPUB; EPO; JPO; DERWENT; USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:45
5	174	DAF-\$5	USPAT; US-PGPUB; EPO; JPO; DERWENT;	2004/01/21 11:51
6	9	DAF-\$5 and DAF-18	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:51
8	617	glucose AND diabet\$5 AND obes\$10 AND elegans	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:52
9	20	DAF-\$5 and (glucose AND diabet\$5 AND obes\$10 AND elegans)	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:57
11	490	PTEN	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:59
12	12	DAF-\$5 and PTEN	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 11:59
13	9	daf-18	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 12:00
14	131	PTEN and transgenic	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 12:12
15	40	(PTEN and transgenic) and elegans	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 12:07
17	48	PTEN and elegans	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 12:07
18	21	PTEN and transgenic.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT; USOCR	2004/01/21 12:12

=> d his

(FILE 'HOME' ENTERED AT 13:22:25 ON 21 JAN 2004)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
AT 13:22:44 ON 21 JAN 2004

L1 7816 S DAF? OR DAF-18 OR DAF18
L2 4962 S PTEN OR MMAC1 OR TEP1
L3 29 S L1 AND L2
L4 13 DUP REM L3 (16 DUPLICATES REMOVED)
L5 13 SORT L4 PY
L6 127 S L2 AND TRANSGENIC
L7 59 DUP REM L6 (68 DUPLICATES REMOVED)
L8 2 S L7 AND (NEMATODE? OR ELEGANS)
L9 62 S L2 AND (NEMATODE? OR ELEGANS)
L10 41 DUP REM L9 (21 DUPLICATES REMOVED)
L11 3 S L10 AND TRANSGEN?
 E RUVKUN G?/AU
L12 95 S E4
L13 2 S L12 AND L3
L14 2 DUP REM L13 (0 DUPLICATES REMOVED)

=> d an ti so au ab pi l14 1-2

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:384548 CAPLUS
DN 133:39116
TI Genes and polypeptides involved in insulin signaling pathways for glucose tolerance, obesity, and longevity and their uses as therapeutic and diagnostic tools
SO PCT Int. Appl., 402 pp.
CODEN: PIXXD2
IN Ruvkun, Gary; Ogg, Scott
AB Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compns. for identifying or treating such conditions. The *Caenorhabditis elegans* metabolic regulatory genes **daf-2** and **age-1** encode homologs of the mammalian insulin receptor/phosphoinositol 3-kinase signaling pathway proteins, resp. Also, the *C. elegans* PKB kinase and AKT kinase act downstream of these genes, as their mammalian homologs act downstream of insulin signaling. The *C. elegans* **PTEN** lipid phosphatase homolog, **DAF-18**, acts upstream of AKT in this signaling pathway. Further, the **DAF-16** forkhead protein represents the major transcriptional output of this insulin signaling pathway. Addnl. evidence indicates that the **DAF-16**, **DAF-3**, **DAF-8**, and **DAF-14** transcriptional outputs of converging signaling pathways regulate metab. The congruence between the *C. elegans* and mammalian insulin signaling pathways strongly supports the contention that new genes identified in the *C. elegans* pathway also act in mammalian insulin signaling. Exemplary sequences and functional characteristics of the *C. elegans* **daf** genes and their human homologs are provided.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000033068	A1	20000608	WO 1999-US28529	19991202
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001029617	A1	20011011	US 1998-205658	19981203
EP 1163515	A1	20011219	EP 1999-960641	19991202
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:37224 CAPLUS
DN 130:220650
TI The *C. elegans* **PTEN** homolog, **DAF-18**, acts in
the insulin receptor-like metabolic signaling pathway
SO Molecular Cell (1998), 2(6), 887-893
CODEN: MOCEFL; ISSN: 1097-2765
AU Ogg, Scott; Ruvkun, Gary
AB An insulin-like signaling pathway, from the **DAF-2** receptor, the
AGE-1 phosphoinositide 3-kinase, and the AKT-1/AKT-2 serine/threonine
kinases to the **DAF-16** Fork head transcription factor, regulates
the metab., development, and life span of *Caenorhabditis elegans*.
Inhibition of **daf-18** gene activity bypasses the normal
requirement for AGE-1 and partially bypasses the need for **DAF-2**
signaling. The suppression of age-1 mutations by a **daf-**
18 mutation depends on AKT-1/AKT-2 signaling, showing that
DAF-18 acts between AGE-1 and the AKT input to
DAF-16 transcriptional regulation. **Daf-18**
encodes a homolog of the human tumor suppressor **PTEN** (
MMAC1/TEP1), which has 3-phosphatase activity toward
phosphatidylinositol 3,4,5-trisphosphate (PIP3). **DAF-18**
PTEN may normally limit AKT-1 and AKT-2 activation by decreasing
PIP3 levels. The action of **daf-18** in this metabolic
control pathway suggests that mammalian **PTEN** may modulate
insulin signaling and may be variant in diabetic pedigrees.

d his

(FILE 'HOME' ENTERED AT 13:22:25 ON 21 JAN 2004)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
AT 13:22:44 ON 21 JAN 2004

L1 7816 S DAF? OR DAF-18 OR DAF18
L2 4962 S PTEN OR MMAC1 OR TEP1
L3 29 S L1 AND L2
L4 13 DUP REM L3 (16 DUPLICATES REMOVED)
L5 13 SORT L4 PY

=>

=> d an ti so au ab pi 15 7 1-4 12

L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:384548 CAPLUS

DN 133:39116

TI Genes and polypeptides involved in insulin signaling pathways for glucose tolerance, obesity, and longevity and their uses as therapeutic and diagnostic tools

SO PCT Int. Appl., 402 pp.
CODEN: PIXXD2

IN Ruvkun, Gary; Ogg, Scott

AB Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compns. for identifying or treating such conditions. The *Ceaeorhabditis elegans* metabolic regulatory genes **daf-2** and **age-1** encode homologs of the mammalian insulin receptor/phosphoinositol 3-kinase signaling pathway proteins, resp. Also, the *C. elegans* PKB kinase and AKT kinase act downstream of these genes, as their mammalian homologs act downstream of insulin signaling. The *C. elegans* **PTEN** lipid phosphatase homolog, **DAF-18**, acts upstream of AKT in this signaling pathway. Further, the **DAF-16** forkhead protein represents the major transcriptional output of this insulin signaling pathway. Addnl. evidence indicates that the **DAF-16**, **DAF-3**, **DAF-8**, and **DAF-14** transcriptional outputs of converging signaling pathways regulate metab. The congruence between the *C. elegans* and mammalian insulin signaling pathways strongly supports the contention that new genes identified in the *C. elegans* pathway also act in mammalian insulin signaling. Exemplary sequences and functional characteristics of the *C. elegans* **daf** genes and their human homologs are provided.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000033068	A1	20000608	WO 1999-US28529	19991202
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2001029617	A1	20011011	US 1998-205658	19981203
EP 1163515	A1	20011219	EP 1999-960641	19991202
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		

L5 ANSWER 1 OF 13 MEDLINE on STN
AN 1999102962 MEDLINE

TI The *C. elegans* **PTEN** homolog, **DAF-18**, acts in the insulin receptor-like metabolic signaling pathway.

SO MOLECULAR CELL, (1998 Dec) 2 (6) 887-93.
Journal code: 9802571. ISSN: 1097-2765.

AU Ogg S; Ruvkun G

AB An insulin-like signaling pathway, from the **DAF-2** receptor, the

AGE-1 phosphoinositide 3-kinase, and the AKT-1/AKT-2 serine/threonine kinases to the **DAF-16** Fork head transcription factor, regulates the metabolism, development, and life span of *Caenorhabditis elegans*. Inhibition of **daf-18** gene activity bypasses the normal requirement for AGE-1 and partially bypasses the need for **DAF-2** signaling. The suppression of age-1 mutations by a **daf-18** mutation depends on AKT-1/AKT-2 signaling, showing that **DAF-18** acts between AGE-1 and the AKT input to **DAF-16** transcriptional regulation. **daf-18** encodes a homolog of the human tumor suppressor **PTEN** (**MMAC1/TEP1**), which has 3-phosphatase activity toward phosphatidylinositol 3,4,5-trisphosphate (PIP3). **DAF-18 PTEN** may normally limit AKT-1 and AKT-2 activation by decreasing PIP3 levels. The action of **daf-18** in this metabolic control pathway suggests that mammalian **PTEN** may modulate insulin signaling and may be variant in diabetic pedigrees.

L5 ANSWER 2 OF 13 MEDLINE on STN
AN 1999307426 MEDLINE
TI The **PTEN** tumor suppressor homolog in *Caenorhabditis elegans* regulates longevity and dauer formation in an insulin receptor-like signaling pathway.
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jun 22) 96 (13) 7427-32.
Journal code: 7505876. ISSN: 0027-8424.
AU Mihaylova V T; Borland C Z; Manjarrez L; Stern M J; Sun H
AB Inactivation of the tumor suppressor **PTEN** gene is found in a variety of human cancers and in cancer predisposition syndromes. Recently, **PTEN** protein has been shown to possess phosphatase activity on phosphatidylinositol 3,4,5-trisphosphate, a product of phosphatidylinositol 3-kinase. We have identified a homolog of **PTEN** in *Caenorhabditis elegans* and have found that it corresponds to the **daf-18** gene, which had been defined by a single, phenotypically weak allele, **daf-18(e1375)**. By analyzing an allele, **daf-18(nr2037)**, which bears a deletion of the catalytic portion of CePTEN/**DAF-18**, we have shown that mutation in **daf-18** can completely suppress the dauer-constitutive phenotype caused by inactivation of **daf-2** or **age-1**, which encode an insulin receptor-like molecule and the catalytic subunit of phosphatidylinositol 3-kinase, respectively. In addition, **daf-18(nr2037)** dramatically shortens lifespan, both in a wild-type background and in a **daf-2** mutant background that normally prolongs lifespan. The lifespan in a **daf-18(nr2037)** mutant can be restored to essentially that of wild type when combined with a **daf-2** mutation. Our studies provide genetic evidence that, in *C. elegans*, the **PTEN** homolog **DAF-18** functions as a negative regulator of the **DAF-2** and **AGE-1** signaling pathway, consistent with the notion that **DAF-18** acts a phosphatidylinositol 3,4,5-trisphosphate phosphatase *in vivo*. Furthermore, our studies have uncovered a longevity-promoting activity of the **PTEN** homolog in *C. elegans*.
L5 ANSWER 3 OF 13 MEDLINE on STN
AN 1999227332 MEDLINE
TI Regulation of dauer larva development in *Caenorhabditis elegans* by **daf-18**, a homologue of the tumour suppressor **PTEN**.
SO CURRENT BIOLOGY, (1999 Mar 25) 9 (6) 329-32.
Journal code: 9107782. ISSN: 0960-9822.
AU Rouault J P; Kuwabara P E; Sinilnikova O M; Duret L; Thierry-Mieg D; Billaud M
AB The tumour suppressor gene **PTEN** (also called **MMAC1** or **TEP1**) is somatically mutated in a variety of cancer types [1] [2] [3] [4]. In addition, germline mutation of **PTEN** is responsible for two dominantly inherited, related cancer syndromes called Cowden disease and Bannayan-Ruvalcaba-Riley syndrome [4]. **PTEN** encodes a dual-specificity phosphatase that inhibits cell spreading and migration partly by inhibiting integrin-mediated signalling [5] [6] [7]. Furthermore, **PTEN** regulates the levels of phosphatidylinositol

3,4,5-trisphosphate (PIP3) by specifically dephosphorylating position 3 on the inositol ring [8]. We report here that the dauer formation gene **daf-18** is the *Caenorhabditis elegans* homologue of **PTEN**. **DAF-18** is a component of the insulin-like signalling pathway controlling entry into diapause and adult longevity that is regulated by the **DAF-2** receptor tyrosine kinase and the **AGE-1** PI 3-kinase [9]. Others have shown that mutation of **daf-18** suppresses the life extension and constitutive dauer formation associated with **daf-2** or **age-1** mutants. Similarly, we show that inactivation of **daf-18** by RNA-mediated interference mimics this suppression, and that a wild-type **daf-18** transgene rescues the dauer defect. These results indicate that **PTEN/daf-18** antagonizes the **DAF-2-AGE-1** pathway, perhaps by catalyzing dephosphorylation of the PIP3 generated by **AGE-1**. These data further support the notion that mutations of **PTEN** contribute to the development of human neoplasia through an aberrant activation of the PI 3-kinase signalling cascade.

L5 ANSWER 4 OF 13 MEDLINE on STN
AN 1999178991 MEDLINE
TI Regulation of the insulin-like developmental pathway of *Caenorhabditis elegans* by a homolog of the **PTEN** tumor suppressor gene.
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Mar 16) 96 (6) 2925-30.
Journal code: 7505876. ISSN: 0027-8424.
AU Gil E B; Malone Link E; Liu L X; Johnson C D; Lees J A
AB The human **PTEN** tumor suppressor gene is mutated in a wide variety of sporadic tumors. To determine the function of **PTEN** in vivo we have studied a **PTEN** homolog in *Caenorhabditis elegans*. We have generated a strong loss-of-function allele of the **PTEN** homolog and shown that the deficient strain is unable to enter dauer diapause. An insulin-like phosphatidylinositol 3-OH kinase (PI3'K) signaling pathway regulates dauer-stage entry. Mutations in either the **daf-2** insulin receptor-like (IRL) gene or the **age-1** encoded PI3'K catalytic subunit homolog cause constitutive dauer formation and also affect the life span, brood size, and metabolism of nondauer animals. Strikingly, loss-of-function mutations in the **age-1** PI3'K and **daf-2** IRL genes are suppressed by loss-of-function mutations in the **PTEN** homolog. We establish that the **PTEN** homolog is encoded by **daf-18**, a previously uncloned gene that has been shown to interact genetically with the **DAF-2** IRL **AGE-1** PI3'K signaling pathway. This interaction provides clear genetic evidence that **PTEN** acts to antagonize PI3'K function in vivo. Given the conservation of the PI3'K signaling pathway between *C. elegans* and mammals, the analysis of **daf-18 PTEN** mutant nematodes should shed light on the role of human **PTEN** in the etiology of metabolic disease, aging, and cancer.

L5 ANSWER 12 OF 13 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2003:79971 SCISEARCH
TI Life span extensions associated with upregulation of gene expression of antioxidant enzymes in *Caenorhabditis elegans*, studies of mutation in the **age-1**, PI3 kinase homologue and short-term exposure to hyperoxia.
SO JOURNAL OF THE AMERICAN AGING ASSOCIATION, (JAN 2002) Vol. 25, No. 1, pp. 21-28.
Publisher: AMER AGING ASSOC, SALLY BALIN MEDICAL CENTER, 110 CHESLEY DR, MEDIA, PA 19063 USA.
ISSN: 0161-9152.
AU Honda Y; Honda S (Reprint)
AB Life span could be modified by genetic or environmental perturbations in *Caenorhabditis elegans*. Here we show that two extensions of life span are associated with oxidative stress resistance and upregulation of the gene expression of antioxidant enzymes. First, mutations in **age-1** gene (PI3 kinase homologue) that confer life span extension, display oxidative stress resistance and increase in the gene expression of **sod-3**, one of two Mn-superoxide dismutases (SOD) and **ctl-1**, cytosolic catalase. In this study, these traits appear to be regulated by the following genetic pathway: **daf-2** (insulin receptor family) -> **daf-**

18 (PTEN homologue) -> age-1 -> daf-16 (Fork head transcription factor family), similar to the genetic pathway for the life span extension. Second, we show that short-term exposure to hyperoxia extends life span slightly but significantly. This treatment increases oxidative stress resistance and the gene expression of three types of SOD isoforms. These results suggest that both of these two life span extensions are closely related with increase in the antioxidant defense function.

=>

109804

From: Kaushal, Sumesh
Sent: Thursday, December 04, 2003 7:09 PM
To: STIC-Biotech/ChemLib
Subject: 09205658: Interference and Seq search

RECEIVED
DEC - 5 2003
(STIC)

09205658: Interference and Seq search

Title: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS

Inventor: RUVKUN, GARY

Please search

SEQ ID NO: 309
SEQ ID NO: 310

S. Kaushal

CM1 12A07 AU1636

Ph: 703-305-6838

Mail Box: 11E12

Point of Contact
P. Sheppard
Telephone number: (703) 308-4499

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: 10/3/03
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____